ACRS · Aclaris Therapeutics, Inc.
$5.33
-0.04 (-0.74%)
At close · Jul 28
Market Cap
$744.41M
Shares
139.66M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.37
Open$5.29
Day$5.20–5.62
52W$1.46–5.88
Avg vol 30d2.1M
Short int13.4M · 9.6% float · 6.9d
Short vol70%
Last earningsMay 7, 2024
DataJan 2020–Jul 2026
Filing10-Q · May 7
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+47%
above
Price vs 50-day avg
+9%
above
RSI (14)
52
neutral
MACD trend
Negative
52-week position
88%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+9%
trailing
6-month return
+53%
trailing
YTD return
+78%
this year
Relative strength
+47%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $4 — 50d above 200d
Institutional flow
Accumulating
19 of 136 funds reported for Jun 30 · net +24.7K sh shares · +4 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.56% of float · ▲ +17.1% MoM · 6.9 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
136 holders — mid 3-yr range
Squeeze score
77
high risk · 0–100
Fundamentals
Gross margin
193%
EPS growth
+69%
Y/Y
Free cash flow
$-47.2M
Balance sheet
$9.3M
net cash
Quant / Vol
risk profile
Volatility
96%
annualized · 1-yr
Max drawdown
−37%
past year
ATR
5.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+47%
Bullish
Price vs 50-day avg
+9%
Bullish
RSI (14)
52
Neutral
MACD trend
Negative
Bearish
52-week position
88%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $5 › 200d $4 — 50d above 200d
Institutional flow
Accumulating
19 of 136 funds reported for Jun 30 · net +24.7K sh shares · +4 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.56% of float · ▲ +17.1% MoM · 6.9 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
136 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1
Now $5 · 88%
52-wk high $6
vs 200-day avg +47%
vs 50-day avg +9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ACRS
this stock
Aclaris Therapeutics, Inc.
|
$744.41M | +78.4% | -58.2% | — | 9.6% |
|
ONC
BeOne Medicines Ltd.
|
$477.60B | +7.3% | +22179.2% | 971.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ACRS | -5.5% | +9.4% | +53.0% | +1.5% | +78.4% |
| SPY | -0.4% | +1.4% | +6.3% | -1.0% | +8.4% |
| vs SPY | -5.1% | +8.0% | +46.7% | +2.5% | +70.0% |
Key facts
CIK
1557746
CUSIP
00461U105
13F (30d)
18 filings
18 filers
Visit website
Investor relations